301 related articles for article (PubMed ID: 15490268)
1. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis.
Papadaki HA; Tsatsanis C; Christoforidou A; Malliaraki N; Psyllaki M; Pontikoglou C; Miliaki M; Margioris AN; Eliopoulos GD
J Bone Miner Metab; 2004; 22(6):577-87. PubMed ID: 15490268
[TBL] [Abstract][Full Text] [Related]
2. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
3. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B
Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
Christopoulou GE; Stavropoulou A; Anastassopoulos G; Panteliou SD; Papadaki E; Karamanos NK; Panagiotopoulos E
J Pharm Biomed Anal; 2006 Jun; 41(3):891-7. PubMed ID: 16488571
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of interleukin-1 and -6 in the etiopathogenesis of idiopathic osteoporosis and osteopenia in children.
Rusińska A; Chlebna-Sokół D
Arch Immunol Ther Exp (Warsz); 2005; 53(3):257-65. PubMed ID: 15995586
[TBL] [Abstract][Full Text] [Related]
6. Effect of alendronate on bone mineral density in adult patients with Laron syndrome (primary growth hormone insensitivity).
Eshed V; Benbassat CA; Laron Z
Growth Horm IGF Res; 2006 Apr; 16(2):119-24. PubMed ID: 16617031
[TBL] [Abstract][Full Text] [Related]
7. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
[TBL] [Abstract][Full Text] [Related]
9. The "lively" cytokines network in beta-Thalassemia Major-related osteoporosis.
Morabito N; Russo GT; Gaudio A; Lasco A; Catalano A; Morini E; Franchina F; Maisano D; La Rosa M; Plota M; Crifò A; Meo A; Frisina N
Bone; 2007 Jun; 40(6):1588-94. PubMed ID: 17412659
[TBL] [Abstract][Full Text] [Related]
10. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
[TBL] [Abstract][Full Text] [Related]
11. Chronic idiopathic neutropenia of adults is associated with decreased bone mineral density and alterations in bone turnover biochemical markers.
Papadaki HA; Margioris AN; Miliaki M; Steriopoulos C; Valatas W; Eliopoulos GD
Eur J Haematol; 1999 May; 62(5):311-6. PubMed ID: 10359059
[TBL] [Abstract][Full Text] [Related]
12. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
13. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
Masaryk P; Stancíková M; Letkovská A; Rovenský J
Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
[TBL] [Abstract][Full Text] [Related]
14. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
[TBL] [Abstract][Full Text] [Related]
15. Low-level lifetime exposure to cadmium decreases skeletal mineralization and enhances bone loss in aged rats.
Brzóska MM; Moniuszko-Jakoniuk J
Bone; 2004 Nov; 35(5):1180-91. PubMed ID: 15542044
[TBL] [Abstract][Full Text] [Related]
16. Alendronate administration and skeletal response during chronic alcohol intake in the adolescent male rat.
Wezeman FH; Emanuele MA; Moskal SF; Steiner J; Lapaglia N
J Bone Miner Res; 2000 Oct; 15(10):2033-41. PubMed ID: 11028458
[TBL] [Abstract][Full Text] [Related]
17. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
18. [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases].
Wang QH; Wu HX; Huang YL; Xue J; Yang XY; Zhu L; Wen LH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1888-91. PubMed ID: 19040000
[TBL] [Abstract][Full Text] [Related]
19. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
Guven Z; Karadag-Saygi E; Unlu-Ozkan F; Akyuz G
Aging Male; 2007 Dec; 10(4):197-201. PubMed ID: 18033629
[TBL] [Abstract][Full Text] [Related]
20. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]